RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects

NCT04252430 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

24

Enrollment

INDUSTRY

Sponsor class

Stopped Due to other phase 3 trial failure to meet primary endpoint

Conditions

Healthy Volunteers
Impaired Renal Function

Interventions

DRUG: MD1003

Sponsor

MedDay Pharmaceuticals SA

Collaborators

[object Object]